Production in yeast of α -galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease

Author： Chiba Yasunori

Publisher： Oxford University Press

ISSN： 1460-2423

Source： Glycobiology, Vol.12, Iss.12, 2002-12, pp. : 821-828

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Enzyme replacement therapy for Fabry disease: lessons from two α-galactosidase A orphan products and one FDA approval

By Desnick Robert J

Expert Opinion on Biological Therapy, Vol. 4, Iss. 7, 2004-07 ,pp. : 1167-1176

Informa Healthcare

Access to resources Recommend Favorite

Enzyme Replacement Therapy of Fabry Disease

By Clarke Joe T. R. Iwanochko R. Mark

Molecular Neurobiology, Vol. 32, Iss. 1, 2005-08 ,pp. : 43-50

Humana Press, Inc

Access to resources Recommend Favorite

Advances in the management of Anderson–Fabry disease:enzyme replacement therapy

By Thadhani Ravi Pastores Gregory M

Expert Opinion on Biological Therapy, Vol. 2, Iss. 3, 2002-03 ,pp. : 325-333

Informa Healthcare

Access to resources Recommend Favorite

Enzyme replacement therapy for Gaucher disease

By Charrow Joel

Expert Opinion on Biological Therapy, Vol. 9, Iss. 1, 2009-01 ,pp. : 121-131

Informa Healthcare

Access to resources Recommend Favorite

α-L-Iduronidase and enzyme replacement therapy for mucopolysaccharidosis I

By Brooks Doug A

Expert Opinion on Biological Therapy, Vol. 2, Iss. 8, 2002-12 ,pp. : 967-976

Informa Healthcare

Access to resources Recommend Favorite